All In MedTech

Device Trial Radar · NCT07588672

Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Jul 15, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Polyrizon Ltd.Not on our public-company list
Sponsor type
Industry
First posted
May 15, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the efficacy, safety, and tolerability of PL-14 Allergy Blocker compared to saline spray in adults with Seasonal Allergic Rhinitis (SAR). PL-14 Allergy Blocker is a non-pharmacological, drug-free intranasal mucoadhesive hydrogel designed to form a mechanical barrier on the nasal mucosa and reduce contact between airborne allergens and the nasal lining. This is a prospective, randomized, single-blind, multi-center clinical investigation in up to 120 participants at up to 8 sites in the United States. Eligible participants with a history of seasonal allergic rhinitis will be randomized in a 1:1 ratio to receive either PL-14 Allergy Blocker or Ayr® Saline Nasal Mist for up to 30 days. The study will evaluate the effect of PL-14 Allergy Blocker on nasal allergy symptoms, quality of life, rescue medication use, and symptom-free days. Safety and local tolerability assessments will also be performed throughout this study period.

Conditions

  • Seasonal Allergic Rhinitis (SAR)
  • Allergic Rhinitis

Interventions

  • PL-14 Allergy BlockerDevice

    PL-14 Allergy Blocker is a non-pharmacological, drug-free intranasal mucoadhesive hydrogel designed to act as a mechanical barrier in the nasal cavity to reduce contact between inhaled allergens and the nasal mucosa.

  • Ayr® Saline Nasal MistDevice

    Ayr® Saline Nasal Mist is a non-medicated isotonic saline nasal spray used as the control comparator in this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in mean daily reflective Total Nasal Symptom Score (rTNSS) between treatment groupsTime frame: 14 treatment days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Sneeze, Wheeze & Itch Associates LLC

    Normal, Illinois · Recruiting

  • The Clinical Research Center, LLC

    St Louis, Missouri · Recruiting

  • Allergy Partners of NJ, PC

    Ocean City, New Jersey · Recruiting

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.